留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

炎症小体介导的细胞焦亡在非酒精性脂肪肝病中的作用及机制

张文杰 孙迪阳 王培

张文杰, 孙迪阳, 王培. 炎症小体介导的细胞焦亡在非酒精性脂肪肝病中的作用及机制[J]. 药学实践与服务, 2020, 38(1): 9-13,41. doi: 10.3969/j.issn.1006-0111.201902051
引用本文: 张文杰, 孙迪阳, 王培. 炎症小体介导的细胞焦亡在非酒精性脂肪肝病中的作用及机制[J]. 药学实践与服务, 2020, 38(1): 9-13,41. doi: 10.3969/j.issn.1006-0111.201902051
ZHANG Wenjie, SUN Diyang, WANG Pei. The role and mechanism of inflammasome-associated pyroptosis in nonalcoholic fatty liver disease[J]. Journal of Pharmaceutical Practice and Service, 2020, 38(1): 9-13,41. doi: 10.3969/j.issn.1006-0111.201902051
Citation: ZHANG Wenjie, SUN Diyang, WANG Pei. The role and mechanism of inflammasome-associated pyroptosis in nonalcoholic fatty liver disease[J]. Journal of Pharmaceutical Practice and Service, 2020, 38(1): 9-13,41. doi: 10.3969/j.issn.1006-0111.201902051

炎症小体介导的细胞焦亡在非酒精性脂肪肝病中的作用及机制

doi: 10.3969/j.issn.1006-0111.201902051

The role and mechanism of inflammasome-associated pyroptosis in nonalcoholic fatty liver disease

  • 摘要: 非酒精性脂肪肝病包含单纯性脂肪肝、非酒精性脂肪肝炎和肝硬化等一系列病变,是造成肝硬化、肝细胞癌症的主要因素和肝脏器官移植的重要诱因。非酒精性脂肪肝的发病机制尚不明确,除了加强运动、改善饮食习惯外,目前尚无公认有效的药物治疗方式。细胞焦亡是一种新发现的程序性细胞死亡方式,依赖于天冬氨酸特异性半胱氨酸蛋白酶1(caspase-1)或caspase-11等介导的炎性小体的激活。细胞焦亡过程中常伴有炎症反应的发生,而炎症小体则是细胞产生焦亡和炎症反应所必需的多聚体蛋白复合物,其主要功能是活化caspase-1,从而间接调控炎症因子白介素1(IL-1)和IL-18的表达和分泌。最近的研究表明,细胞焦亡和炎症小体在非酒精性脂肪肝病的发生发展中起重要作用。针对该领域的最新研究进行综述,以期为非酒精性脂肪肝的防治提供新的科学认识和信息。
  • [1] VILLANUEVA M T. Conscious uncoupling in NASH[J]. Nat Rev Drug Discov,2017,16(4):239
    [2] NEUSCHWANDER-TETRI B A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites[J]. Hepatology,2010,52(2):774-788
    [3] MARRA F, SVEGLIATI-BARONI G. Lipotoxicity and the gut-liver axis in NASH pathogenesis[J]. J Hepatol,2018,68(2):280-295
    [4] PEVERILL W, POWELL L, SKOIEN R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation[J]. Int J Mol Sci,2014,15(5):8591-8638
    [5] LAZIC M, INZAUGARAT M E, POVERO D, et al. Reduced dietary omega-6 to omega-3 fatty acid ratio and 12/15-lipoxygenase deficiency are protective against chronic high fat diet-induced steatohepatitis[J]. Plos One,2014,9(9):e107658
    [6] ABDELMALEK M F, SUZUKI A, GUY C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease[J]. Hepatology,2010,51(6):1961-1971
    [7] IOANNOU G N, VAN ROOYEN D M, SAVARD C, et al. Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH[J]. J Lipid Res,2015,56(2):277-285
    [8] MIELE L C, MARRONE G, LAURITANO C, et al. Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target[J]. Curr Pharm Des,2013,19(29):5314-5324
    [9] SCHRODER K, TSCHOPP J. The inflammasomes[J]. Cell,2010,140(6):821-832
    [10] MINKIEWICZ J, DE RIVERO VACCARI J P, KEANE R W. Human astrocytes express a novel NLRP2 inflammasome[J]. Glia,2013,61(7):1113-1121
    [11] Wlodarska M, Thaiss CA, Nowarski R, et al. NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion[J]. Cell,2014,156(5):1045-1059
    [12] OHASHI K, WANG Z J, YANG Y M, et al. NOD-like receptor C4 inflammasome regulates the growth of colon cancer liver metastasis in NAFLD[J]. Hepatology,2019:30693
    [13] DING J J, WANG K, LIU W, et al. Pore-forming activity and structural autoinhibition of the gasdermin family[J]. Nature,2016,535(7610):111-116
    [14] WREE A, MCGEOUGH M D, PEÑA C A, et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD[J]. J Mol Med,2014,92(10):1069-1082
    [15] MATSUZAKA T, ATSUMI A, MATSUMORI R, et al. Elovl6 promotes nonalcoholic steatohepatitis[J]. Hepatology,2012,56(6):2199-2208
    [16] WEN H T, GRIS D, LEI Y, et al. Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin signaling[J]. Nat Immunol,2011,12(5):408-415
    [17] WREE A, EGUCHI A, MCGEOUGH M D, et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice[J]. Hepatology,2014,59(3):898-910
    [18] MRIDHA A R, WREE A, ROBERTSON A A B, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice[J]. J Hepatol,2017,66(5):1037-1046
    [19] YANG S J, LIM Y. Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation[J]. Metabolism,2014,63(5):693-701
    [20] XU B, JIANG M, CHU Y, et al. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice[J]. J Hepatol,2018,68(4):773-782
    [21] MIURA K, KODAMA Y, INOKUCHI S, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1β in mice[J]. Gastroenterology,2010,139(1):323-334.e7
    [22] STIENSTRA R, SAUDALE F, DUVAL C, et al. Kupffer cells promote hepatic steatosis via interleukin-1β-dependent suppression of peroxisome proliferator-activated receptor α activity[J]. Hepatology,2010,51(2):511-522
    [23] VANDANMAGSAR B, YOUM Y, RAVUSSIN A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance[J]. Nat Med,2011,17(2):179-188
    [24] PETRASEK J, BALA S S, CSAK T, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice[J]. J Clin Invest,2012,122(10):3476-3489
    [25] WITEK R P, STONE W C, KARACA F G, et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis[J]. Hepatology,2009,50(5):1421-1430
    [26] KIM S H, KIM G, HAN D H, et al. Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition[J]. Autophagy,2017,13(10):1767-1781
    [27] HENAO-MEJIA J, ELINAV E, JIN C C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity[J]. Nature,2012,482(7384):179-185
    [28] DE MINICIS S, RYCHLICKI C, AGOSTINELLI L, et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice[J]. Hepatology,2014,59(5):1738-1749
    [29] CSAK T, PILLAI A, GANZ M, et al. Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis[J]. Liver Int,2014,34(9):1402-1413
    [30] MURPHY A J, KRAAKMAN M J, KAMMOUN H L, et al. IL-18 production from the NLRP1 inflammasome prevents obesity and metabolic syndrome[J]. Cell Metab,2016,23(1):155-164
    [31] ANITHA M, REICHARDT F, TABATABAVAKILI S, et al. Intestinal dysbiosis contributes to the delayed gastrointestinal transit in high-fat diet fed mice[J]. Cell Mol Gastroenterol Hepatol,2016,2(3):328-339
    [32] CHEN G Y, LIU M C, WANG F Y, et al. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis[J]. J Immunol,2011,186(12):7187-7194
    [33] ZHANG Q, RAOOF M, CHEN Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury[J]. Nature,2010,464(7285):104-107
    [34] SUN Q, LOUGHRAN P, SHAPIRO R, et al. Redox-dependent regulation of hepatocyte absent in melanoma 2 inflammasome activation in sterile liver injury in mice[J]. Hepatology,2017,65(1):253-268
    [35] WATANABE A, SOHAIL M A, GOMES D A, et al. Inflammasome-mediated regulation of hepatic stellate cells[J]. Am J Physiol Gastrointest Liver Physiol,2009,296(6):G1248-G1257
    [36] WREE A, MCGEOUGH M D, INZAUGARAT M E, et al. NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL-17 and TNF in mice[J]. Hepatology,2018,67(2):736-749
  • [1] 陈枫, 杨慈荣, 张圳, 陈飞, 刘霞.  基于药物重定位建立以α1酸性糖蛋白为靶点的高通量筛选平台及潜在减肥药物的发现 . 药学实践与服务, 2024, 42(3): 114-120. doi: 10.12206/j.issn.2097-2024.202309057
    [2] 史小飞, 陈弋, 向科发, 张慧敏, 高越, 刘霞.  以抗炎为潜在靶点的治疗糖尿病肾病的新药研究进展 . 药学实践与服务, 2023, 41(10): 581-585, 628. doi: 10.12206/j.issn.2097-2024.202109068
    [3] 胡朦, 毕娟.  炔诺酮致药物性肝损伤1例 . 药学实践与服务, 2021, 39(1): 94-96. doi: 10.12206/j.issn.1006-0111.202002073
    [4] 蔡孟成, 金永生, 郑巍, 袁梓珂, 郭良君.  基于网络药理学对降脂护肝胶囊干预脂肪肝的机制研究 . 药学实践与服务, 2021, 39(3): 232-239, 248. doi: 10.12206/j.issn.1006-0111.202006054
    [5] 华荣, 陈瑶.  益母草碱抑制NLRP3炎症小体过度激活调控巨噬细胞M1/M2表型分化 . 药学实践与服务, 2021, 39(2): 143-147. doi: 10.12206/j.issn.1006-0111.202101003
    [6] 姜晓娜, 潘俊杰, 于亚男, 田字彬.  硫普罗宁联合谷胱甘肽治疗对非酒精性脂肪肝患者生化指标的影响 . 药学实践与服务, 2021, 39(5): 465-467, 475. doi: 10.12206/j.issn.1006-0111.202103002
    [7] 王斌, 蔡敏, 黄玲, 姜子廷, 童敏思, 李力.  益生菌对非酒精性脂肪肝相关细胞的作用 . 药学实践与服务, 2018, 36(5): 409-416. doi: 10.3969/j.issn.1006-0111.2018.05.006
    [8] 卞莹莹, 王洁, 李安, 开国银, 陆一鸣.  炎症性肠病的药物治疗现状 . 药学实践与服务, 2017, 35(3): 197-200,228. doi: 10.3969/j.issn.1006-0111.2017.03.002
    [9] 杜秀明, 张子腾, 宗英, 余琛琳, 张晓冬, 陆国才.  炎症小体与中枢神经系统疾病 . 药学实践与服务, 2016, 34(1): 12-15. doi: 10.3969/j.issn.1006-0111.2016.01.004
    [10] 何丽娟, 张军东, 安毛毛, 姜远英.  肠道微生态与炎症性肠病 . 药学实践与服务, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001
    [11] 诸德源, 王一然, 蔡国君, 徐添颖.  烟碱乙酰胆碱受体作为镇痛靶点的研究进展 . 药学实践与服务, 2015, 33(4): 309-312,375. doi: 10.3969/j.issn.1006-0111.2015.04.005
    [12] 江海龙, 王宁远, 陆一鸣.  肿瘤坏死因子受体选择性拮抗剂的研究进展 . 药学实践与服务, 2015, 33(5): 392-395. doi: 10.3969/j.issn.1006-0111.2015.05.003
    [13] 林峰, 周志军, 张晨虹, 刘芳, 郭闻渊, 魏若菡, 陈慧.  用乌司他丁抑制炎症反应减轻大鼠移植肝再灌注损伤的实验研究 . 药学实践与服务, 2014, 32(2): 110-113,127. doi: 10.3969/j.issn.1006-0111.2014.02.009
    [14] 龚纯贵, 王彬, 战旗, 金柔男, 姜云霞, 晏建军.  肝切除术后全身性炎症反应发生率及其影响因素分析 . 药学实践与服务, 2012, 30(5): 361-364. doi: 10.3969/j.issn.1006-0111.2012.05.012
    [15] 张苏江, 林璐.  缬沙坦胶囊治疗伴有非酒精性脂肪肝的高血压患者的疗效观察 . 药学实践与服务, 2012, 30(4): 299-301.
    [16] 李帆, 芮耀诚.  IRAK-4在白介素-1受体/Toll样受体(IL-1R/TLRs)介导的炎症信号通路中的关键作用 . 药学实践与服务, 2011, 29(1): 1-3,14.
    [17] 夏爱军, 张琪, 张云波, 梁园, 唐哲, 周宁宁.  舒肝安乐宁浸膏对小鼠急性酒精性肝损伤保护作用的研究 . 药学实践与服务, 2011, 29(5): 366-368.
    [18] 黄海强, 李慧梁, 汤健, 苏娟, 张卫东.  前列腺癌治疗新靶点——hedgehog通路 . 药学实践与服务, 2008, (4): 249-251.
    [19] 丁力, 丁家崇, 郭葆玉.  抗肿瘤药物新靶点半胱天冬酶-10 . 药学实践与服务, 2006, (2): 76-79.
    [20] 胡宏岗, 赵庆杰, 张俊, 吴秋业, 刘超美, 徐建明.  抗真菌药物作用靶位的研究进展 . 药学实践与服务, 2005, (2): 65-71.
  • 加载中
计量
  • 文章访问数:  4539
  • HTML全文浏览量:  522
  • PDF下载量:  3329
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-02-22
  • 修回日期:  2019-07-18

炎症小体介导的细胞焦亡在非酒精性脂肪肝病中的作用及机制

doi: 10.3969/j.issn.1006-0111.201902051

摘要: 非酒精性脂肪肝病包含单纯性脂肪肝、非酒精性脂肪肝炎和肝硬化等一系列病变,是造成肝硬化、肝细胞癌症的主要因素和肝脏器官移植的重要诱因。非酒精性脂肪肝的发病机制尚不明确,除了加强运动、改善饮食习惯外,目前尚无公认有效的药物治疗方式。细胞焦亡是一种新发现的程序性细胞死亡方式,依赖于天冬氨酸特异性半胱氨酸蛋白酶1(caspase-1)或caspase-11等介导的炎性小体的激活。细胞焦亡过程中常伴有炎症反应的发生,而炎症小体则是细胞产生焦亡和炎症反应所必需的多聚体蛋白复合物,其主要功能是活化caspase-1,从而间接调控炎症因子白介素1(IL-1)和IL-18的表达和分泌。最近的研究表明,细胞焦亡和炎症小体在非酒精性脂肪肝病的发生发展中起重要作用。针对该领域的最新研究进行综述,以期为非酒精性脂肪肝的防治提供新的科学认识和信息。

English Abstract

张文杰, 孙迪阳, 王培. 炎症小体介导的细胞焦亡在非酒精性脂肪肝病中的作用及机制[J]. 药学实践与服务, 2020, 38(1): 9-13,41. doi: 10.3969/j.issn.1006-0111.201902051
引用本文: 张文杰, 孙迪阳, 王培. 炎症小体介导的细胞焦亡在非酒精性脂肪肝病中的作用及机制[J]. 药学实践与服务, 2020, 38(1): 9-13,41. doi: 10.3969/j.issn.1006-0111.201902051
ZHANG Wenjie, SUN Diyang, WANG Pei. The role and mechanism of inflammasome-associated pyroptosis in nonalcoholic fatty liver disease[J]. Journal of Pharmaceutical Practice and Service, 2020, 38(1): 9-13,41. doi: 10.3969/j.issn.1006-0111.201902051
Citation: ZHANG Wenjie, SUN Diyang, WANG Pei. The role and mechanism of inflammasome-associated pyroptosis in nonalcoholic fatty liver disease[J]. Journal of Pharmaceutical Practice and Service, 2020, 38(1): 9-13,41. doi: 10.3969/j.issn.1006-0111.201902051
参考文献 (36)

目录

    /

    返回文章
    返回